Janchor Partners, RA Capital Management, Hillhouse Capital, and Jiashan SDIC have invested a USD310m Series C for China-based biopharmaceutical company Everest Medicines, with participation from Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, and Octagon Investments. Existing backers CBC Group, Cormorant Asset Management, Pavilion Capital, and HBM Healthcare Investments made follow-on investments. Read more